Product
Ficlatuzumab
Aliases
AV-299
2 clinical trials
20 indications
Indication
Head and Neck Squamous Cell CarcinomaIndication
Basaloid CarcinomaIndication
Oropharyngeal Squamous Cell CarcinomaIndication
Oral Cavity Squamous Cell CarcinomaIndication
Nasopharyngeal CarcinomaIndication
Head and Neck CancerIndication
Oropharyngeal CancerIndication
HNSCCIndication
Oral Squamous Cell CarcinomaClinical trial
A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)Status: Recruiting, Estimated PCD: 2027-08-01
Clinical trial
A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus: Completed, Estimated PCD: 2022-03-29